General

Roots Analysis has announced the addition of “Bacteriophage Therapeutics Market, 2022-2035” report to its list of offerings.   Key Market Insights Over 100 bacteriophage therapeutics have either been marketed / are being developed by various well-established and small firms; majority of these therapeutics are being evaluated for the treatment of infectious diseases Around 50% of the pipeline candidates are currently under clinical phase of development; of these, close to 50% are designed for oral and topical administration Multiple clinical studies, evaluating various types of bacteriophage therapeutics among more than 3,000 patients across different centers / hospitals, have been registered worldwide Over the years, the intellectual capital related to bacteriophage therapeutics has grown at a significant pace, with several patents being filed by both industry and non-industry players A notable increase in published scientific literature related to bacterio-phage therapeutics has been observed over the years, demonstrating the growing interest in this domain Various organizations have extended financial support to aid the ongoing research for bacteriophage therapies; currently, the focus, in terms of funds disbursed, is on clinical investigation of bacteriophage therapeutics Several investors, having realized the benefits and future opportunity, have invested over USD 1 billion since 2017 The rising interest of stakeholders is also reflected by the number of partnerships signed in the recent past, involving players located in different geographical regions Our proprietary start-up health indexing analysis confirms the presence of several new entrants that claim to possess the required capabilities for developing bacteriophage therapeutics The bacteriophage market is anticipated to grow at a CAGR of ~10% till 2035; the forecasted opportunity is likely to be distributed across different therapeutic areas, routes of administration, and geographical regions   Table of Content 1.                     PREFACE 1.1.                  Scope of the Report 1.2.                  Market Segmentations 1.3.                  Research Methodology 1.4.                  Key Questions Answered 1.5.                  Chapter Outlines   2.                     EXECUTIVE SUMMARY   3.                     INTRODUCTION 3.1.                  Chapter Overview 3.2.                  Historical Evolution of Bacteriophages 3.3.                  Biology of Bacteriophages 3.4.                  Introduction to Bacteriophage Therapy 3.5.                  Applications of Bacteriophage Therapy 3.6.                  Advantages of Bacteriophage Therapy 3.7.                  Limitations of Bacteriophage Therapy 3.8.                  Conclusion   4.                     BACTERIOPHAGE THERAPEUTICS: MARKET LANDSCAPE 4.1.                  Chapter Overview 4.2.                  Bacteriophage Therapeutics: Drug Pipeline 4.2.1.               Analysis by Phase of Development 4.2.2.               Analysis by Therapeutic Area 4.2.3.               Analysis by Phase of Development and Therapeutic Area 4.2.4.               Analysis by Targeted Bacterial Strain 4.2.5.               Analysis by Target Disease Indication 4.2.6.               Analysis by Type of Therapy 4.2.7.               Analysis by Route of Administration   4.3.                  Information on Bacteriophage Related Technologies   5.                     BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE 5.1.                  Chapter Overview 5.2.                  Bacteriophage Therapeutics: List of Developers 5.2.1.               Analysis by Year of Establishment 5.2.2.               Analysis by Company Size 5.2.3.               Analysis by Location of Headquarters 5.2.4.               Analysis by Company Size and Location of Headquarters 5.2.5.               Leading Developers: Analysis by Number of Bacteriophage Therapeutics   6.                     COMPANY AND DRUG PROFILES 6.1.                  Chapter Overview 6.2.                  Eliava BioPreparations 6.3.                  Micreos 6.4.                  NPO Microgen 6.5.                  ContraFect 6.6.                  Adaptive Phage Therapeutics 6.7.                  Phagelux 6.8.                  Pherecydes Pharma   7.                     CLINICAL TRIAL ANALYSIS 7.1.                  Chapter Overview 7.2.                  Scope and Methodology   7.3.                  Bacteriophage Therapeutics Market: Clinical Trial Analysis   8.                     PATENT ANALYSIS 8.1.                  Chapter Overview 8.2.                  Scope and Methodology   8.3.                  Bacteriophage Therapeutics: Patent Analysis   8.4.                  Bacteriophage Therapeutics: Patent Benchmarking 8.5.                  Bacteriophage Therapeutics: Patent Valuation 8.6.                  List of Leading Patents   9.                     PUBLICATION BENCHMARKING ANALYSIS 9.1.                  Chapter Overview 9.2.                  Scope and Methodology 9.3.                  Publication Benchmarking   10.                   ACADEMIC GRANTS ANALYSIS 10.1.                Chapter Overview 10.2.                Scope and Methodology   10.3.                Bacteriophage Therapeutics: Academic Grant Analysis   11.                   FUNDING AND INVESTMENT ANALYSIS 11.1.                Chapter Overview 11.2.                Types of Funding 11.3.                Bacteriophage Therapeutics Market: List of Funding and Investments 11.4.                Concluding Remarks   12.                   PARTNERSHIPS AND COLLABORATIONS 12.1.                Chapter Overview 12.2.                Partnership Models 12.3.                Bacteriophage Therapeutics: List of Partnerships and Collaborations   13.                   START-UP HEALTH INDEXING 13.1.                Chapter Overview 13.2.                Bacteriophage Therapeutics Developers: Start-ups 13.3.                Benchmarking of Start-ups   14.                   MARKET FORECAST AND OPPORTUNITY ANALYSIS 14.1.                Chapter Overview 14.2.                Scope and Assumptions 14.3.                Forecast Methodology 14.4.                Global Bacteriophage Therapeutics Market, 2022-2035   15.                   CONCLUSION   16.                   EXECUTIVE INSIGHTS 16.1.                Chapter Overview 16.2.                Rime Bioinformatics 16.2.1.             Company Snapshot 16.2.2.             Interview Transcript: Antoine Culot, Chief Executive Officer   16.3.                BiomX 16.4.                Hospices Civils De Lyon 16.5.                Independent Consultant             17.                   APPENDIX I: TABULATED DATA   18.                   APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS   For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html   You may also be interested in the following titles: Nanoparticle Formulation Market mRNA Therapeutics and mRNA Vaccines Industry: Current Scenario and Future Trends Cell Therapy Manufacturing Market Roots Analysis Consulting - the preferred research partner for global firms   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com    

Roots Analysis has done a detailed study on Deep Learning in Drug Discovery and Deep Learning in Diagnostics Market, covering important aspects of the industry and identifying key future growth opportunities.   Key Market Insights Presently, more than 70 players across the globe claim to offer deep learning technologies for potential applications across various steps of drug discovery and development process Majority (70%) of the stakeholders employ proprietary deep learning-based technologies in drug discovery to offer big data analysis  Nearly 50% of the deep learning-based diagnostic providers are based in North America; most such players offer technologies for use across medical imaging and medical diagnosis related applications Around 70% of the players engaged in offering deep learning solutions for diagnostics have been established post-2011; majority of the players offer solutions focused on oncological disorders Foreseeing the lucrative potential, a large number of players have made investments worth over USD 15 billion, across 210 funding instances, to advance the initiatives undertaken by industry stakeholders Over the past few years, more than 704,000 patients have been recruited / enrolled in clinical trials registered for deep learning-based solutions / diagnostics across different geographies Our proprietary benchmarking analysis, based on a variety of parameters, indicates the leading start-ups / small firms that are spearheading innovation in this domain    Some players have managed to establish strong competitive positions; in the near future, we expect multiple acquisitions to take place wherein the relative valuation of a firm is likely to be a key determinant Increasing adoption of deep learning technologies in the life sciences and healthcare industry is anticipated to create profitable business opportunities for the technology developers The market opportunity associated with deep learning in drug discovery is expected to witness an annualized growth rate of 23% over the coming 12 years In the long term, the opportunity for deep learning in diagnostics is projected to grow exponentially; the market is likely to be well distributed across various therapeutic areas and geographical regions   Table of Contents   1.                PREFACE 1.1.             Introduction 1.2.             Key Market Insights 1.3.             Scope of the Report 1.4.             Research Methodology 1.5.             Frequently Asked Questions 1.6.             Chapter Outlines   2.                EXECUTIVE SUMMARY   3.                INTRODUCTION 3.1.             Humans, Machines and Intelligence 3.2.             The Science of Learning 3.3.             The Big Data Revolution 3.4.             Deep Learning in Healthcare 3.5.             Concluding Remarks   4.                MARKET OVERVIEW: DEEP LEARNING IN DRUG DISCOVERY 4.1.             Chapter Overview 4.2.             Deep Learning in Drug Discovery: Overall Market Landscape of Service / Technology Providers   5.                MARKET OVERVIEW: DEEP LEARNING IN DIAGNOSTICS 5.1.             Chapter Overview 5.2.             Deep Learning in Diagnostics: Overall Market Landscape of Service / Technology Providers   6.                COMPANY PROFILES 6.2.             Aegicare 6.2.1.          Company Overview 6.2.2.          Service Portfolio 6.2.3.          Recent Developments and Future Outlook   6.3.             Aiforia Technologies 6.4.             Ardigen 6.5.             Berg 6.6.             Google 6.7.             Huawei 6.8.             Merative 6.9.             Nference 6.10.           Nvidia 6.11.           Owkin 6.12.           Phenomic AI 6.13.           Pixel AI   7.                PORTER’S FIVE FORCES ANALYSIS 7.1.             Chapter Overview 7.2.             Methodology and Assumptions 7.3.             Key Parameters 7.4.             Concluding Remarks   8.                CLINICAL TRIAL ANALYSIS 8.1.             Chapter Overview 8.2.             Scope and Methodology 8.3              Deep Learning Market: Clinical Trial Analysis   9.                FUNDING AND INVESTMENT ANALYSIS 9.1.             Chapter Overview 9.2.             Types of Funding 9.3.             Deep Learning Market: Funding and Investment Analysis   10.              START-UP HEALTH INDEXING 10.1.           Chapter Overview 10.2.           Start-ups Focused on Deep Learning in Drug Discovery 10.3.           Benchmarking Analysis of Start-ups Focused on Deep Learning in Drug Discovery 10.4.           Start-ups Focused on Deep Learning in Diagnostics 10.5.           Benchmarking Analysis of Start-ups Focused on Deep Learning in Diagnostics 10.5.1.        Analysis by Focus Area   11.              COMPANY VALUATION ANALYSIS 11.1.           Chapter Overview 11.2.           Company Valuation Analysis: Key Parameters 11.3.           Methodology 11.4.           Company Valuation Analysis: Roots Analysis Proprietary Scores   12.              MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DRUG DISCOVERY 12.1.           Chapter Overview 12.2.           Key Assumptions and Methodology 12.3.           Overall Deep Learning in Drug Discovery Market, 2023-2035   13.              MARKET SIZING AND OPPORTUNITY ANALYSIS: DEEP LEARNING IN DIAGNOSTICS 13.1.           Chapter Overview 13.2.           Key Assumptions and Methodology 13.3.           Overall Deep Learning in Diagnostics Market, 2023-2035   14.              DEEP LEARNING IN HEALTHCARE: EXPERT INSIGHTS   15.              CONCLUDING REMARKS   16.              INTERVIEW TRANSCRIPTS 16.1.           Chapter Overview 16.2.           Nucleai 16.3.           Mediwhale 16.4.           Arterys 16.5.           AlgoSurg 16.6.           ContextVision 16.7.           Advenio Technosys 16.8.           Arterys 16.9.           Arya.ai   17.              APPENDIX 1: TABULATED DATA   18.              APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS   To view more details on this report, click on the link https://www.rootsanalysis.com/reports/view_document/deep-learning-in-drug-discovery-market/156.html   You may also be interested in the following titles: Decentralized Clinical Trials / Virtual Clinical Trials Market  Exploring AI-based Digital Pathology Medical Device Coatings Market Roots Analysis Consulting - the preferred research partner for global firms   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com    

The growing concern of patient non-compliance and poor adherence to conventional medication regimen has prompted various biopharmaceutical companies to leverage the expertise of players offering long-acting drug delivery technologies and services   Roots Analysis is pleased to announce the publication of its recent study, titled, “Long-Acting Drug Delivery Market, 2023-2035”   The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes   An executive summary of the insights captured during our research. It offers a high-level view on the current state of long acting drugs delivery technologies and services market and its likely evolution in the mid-long term. A general overview of long-acting drug delivery and the different types of long-acting drug delivery systems. Additionally, it highlights the underlying principles and strategies associated with long-acting drug delivery. A detailed assessment of the current technology landscape of long-acting drug delivery technologies. A detailed assessment of the overall service providers landscape of the companies offering contract services related to long-acting drug delivery. A technology competitiveness analysis of long-acting drug delivery technologies. A company competitiveness analysis of long-acting drug delivery service providers. Elaborate profiles of prominent players developing technologies and offering services in the domain of long-acting drug delivery (shortlisted based on a proprietary criterion). A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2018. A detailed analysis of over 570 peer-reviewed, scientific articles focused on research related to long-acting drug delivery. An in-depth analysis of various patents that have been filed / granted related to long-acting drug delivery, since 2018. A detailed review of academic grants that have been awarded to various research institutes for projects focused on long-acting drug delivery, since 2018. A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) Principle Manipulation of drug release from delivery systems Manipulation of in vivo clearance   Strategy Chemical Modification Micro-encapsulation Long-Acting Hydrogels Long-Acting Implants Long-Acting Microneedles Multivesicular Liposomes Nanocrystal Suspensions Protein Fusion   Compatible Dosage Form Injectables Implantables Oral Dosage Forms Topical / Transdermal Dosage Forms Vaginal Dosage Forms Other Dosage Forms   Type of Molecules Delivered Small Molecules Biologics Other Molecules   Type of Material Used Polymer based Non-polymer based   Key Geographical Regions North America Europe Asia-Pacific Middle East and North Africa   Key companies covered in the report Adare Pharma Solutions AMW Bostal Drug Delivery Creative Biolabs ForDoz Pharma Innocore Pharmaceuticals Integral BioSystems LATITUDE Pharmaceuticals Navin Saxena Research and Technology Centre (NSRT) Samyang Biopharm   To view more details on this report, click on the link https://www.rootsanalysis.com/reports/long-acting-drug-delivery-market.html   You may also be interested in the following titles: Oral Solid Dosage Manufacturing Market Lipid Nanoparticles in Drug Delivery Bioavailability enhancement services market Global Gene Switch Market             About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com  

The “Bispecific Antibodies Market report features an in-depth analysis, highlighting the pipeline of various players engaged in this domain.   Roots Analysis has announced the addition of “Bispecific Antibodies Market, 2023-2035” report to its list of offerings.   Key Inclusions A detailed review of the market landscape of over 220 bispecific antibodies that are either approved or being evaluated in different stages of clinical development, based on several relevant parameters, such as developer company, phase of development, target antigen, type of therapy, route of administration, method of administration, target indication, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer. An in-depth assessment of the market landscape of over 180 bispecific antibodies that are currently being evaluated in preclinical studies, based on several relevant parameters, such as developer company, stage of development, target antigen, therapeutic area, disease segment, year of establishment, company size and location of headquarters of the developer. A detailed assessment of over 80 technology platforms being developed / used by various drug developers for the production of bispecific antibody therapeutics, featuring a 3-D comparative bubble analyses of bispecific antibody technology platforms based on multiple relevant parameters, such as clinical / preclinical pipeline strength, developer’s years of experience, company size and location of headquarters of developers. An in-depth analysis of big pharma players engaged in this domain, featuring insightful spider web analyses of such players, based on clinical stage competition, marketed drugs competition, clinical trial activity, partnership activity and technology portfolio strength. Additionally, it features heat map analyses, highlighting the comparison of big pharma players based on various relevant parameters, such as target antigen, antibody format, mechanism of action and target therapeutic area. Elaborate profiles of prominent drug developers engaged in the development of bispecific antibodies, featuring a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters, key members of the executive team, financial details / information (if available), drug portfolio, recent developments and an informed future outlook. An insightful analysis of various partnerships inked between stakeholders engaged within the bispecific antibody therapeutics domain, during the period 2016-2023, based on several relevant parameters, such as year of partnership, type of partnership, disease segment, type of payment model employed, deal amount, most active players (in terms of number of deals inked), most popular technologies (in terms of number of deals inked for technologies) and regional distribution of partnership activity. An in-depth analysis of ongoing and planned studies related to bispecific antibody therapeutics, which were registered till April 2023, taking into consideration several relevant parameters, such as trial registration year, trial phase, trial recruitment status, enrolled patient population, type of study, study design, type of sponsor / collaborator, leading industry and non-industry players, key focus areas and geographical location of trials. A review of different channels used for promoting marketed bispecific antibodies, along with examples of players that have undertaken such initiatives, elaborating on the various promotional strategies being adopted by developers of two approved bispecific antibodies (chosen based on their popularity in this domain), namely Blincyto™ and Hemlibra®, and comparison of both the drugs based on information available on their respective websites. A discussion on important, industry-specific trends, key market drivers and challenges, under a SWOT framework, featuring a qualitative Harvey ball analysis highlighting the relative impact of each SWOT parameter on the overall market.   The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below: Therapeutic Area Autoimmune Disorders Genetic Disorders Hematological Malignancies Ophthalmic Disorders Skin Cancers Solid Tumors   Mechanism of Action Cytokines Retargeting / Neutralization Dual Ligands Blocking Resistance Factors Co-targeting Targeting Tumor Angiogenesis T-Cell Retargeting / Activation Others   Target Antigen C5-Albumin CD20 x CD3 CD3 x BCMA CD3 x CD19 EGFR x cMET EpCAM x CD3 Factor IXa x Factor X gp100 x CD3 HER2 x HER2 PD-1 x CTLA-4 PD-L1 x TGFβ TNF-α x HSA VEGF x DLL4 VEGF-A x ANG2   Antibody Format Asymmetric Fragments   Key Players Akeso Biopharma Alexion Amgen Genmab Immunocore Janssen Research & Development Linton Pharm Merck OncXerna Therapeutics Pfizer Roche Taisho Pharmaceutical Zymeworks   Key Geographical Regions Asia Europe North America Rest of the World   Key Questions Answered What is the overall size of the global bispecific antibody therapies market? What is the rate at which the bispecific antibodies market is likely to grow in the coming years? Which region has the highest growth rate in the bispecific antibodies market? Who are the leading players engaged in this market? How many players are engaged in developing bispecific antibodies? What are the most common antigens targeted by bispecific antibody therapeutics? Which target indication covers the largest share in bispecific antibody therapies market? What is the partnership and collaboration trend in the bispecific antibody therapeutics domain? What are the upcoming trends in bispecific antibody therapies market?     To view more details on this report, click on the link https://www.rootsanalysis.com/reports/view_document/bispecific-antibodies/286.html   You may also be interested in the following titles: Medical Device Coatings and Surface Modification Technologies Market mRNA Synthesis and Manufacturing Services Market                      About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com  

The “Investor Series: Opportunities in Women’s Digital Health Market’’ report provides detailed information on the women’s digital health market, covering the core and peripheral women’s digital health solutions   Key Inclusions An executive summary of the insights captured during our research. It offers a high-level view on the current state of women’s digital health market and its likely evolution in the mid-long term along with the financial activity in this domain. An introduction to women’s digital health, highlighting some of the key application areas of the FemTech industry. It features various types of women’s digital health products / solutions that have either been marketed / are under development. In addition, the report highlights prominent barriers to the development and success of women’s digital health solutions, and the opinions of representatives from key stakeholder companies involved in this domain. A detailed analysis of women’s digital health focused companies that were established post-2006, featuring key insights on the observed trends related to the basic company parameters, such as year of establishment, location of headquarters, company size, and type of venture.  An assessment of the various products / solutions, offered by the innovator companies, featuring analysis based on number and types of products. Based on the aforementioned insights, we have developed a quantitative perspective on the relative health (based on the company details, product portfolio, financing activity, estimated revenues and profits) of the different innovator companies that have been described in detail in this report. This analysis is based on a proprietary scoring criterion, informed via secondary research. An informed perspective on the value proposition of the companies captured in the report based on multiple relevant aspects, namely product-related value, value to patients, developer value and outreach-related value. A company competitiveness analysis, which offers a quantitative basis for comparing the strengths / contributions of various industry stakeholders that are involved in providing women’s digital health solutions. It is worth mentioning that this analysis is based on the insights generated from the abovementioned relative health indexing and value proposition analysis. A detailed analysis of the women's digital health funding women's digital health investment activity that has taken place, since 2011. It also includes category-wise financing trends, describing the relative maturity (in terms of number of funding instances and total capital raised) of the innovator companies mentioned in the report. Further, it features a list of the leading investors in women’s digital health, based on their participation in financing activity in this industry segment. An elaborate review of the overall women’s digital health market from a financial perspective, including detailed fundamental (insights from the balance sheet and key financial ratios) and technical analysis (insights from historical and recent stock price variations as well as analysis using popular stock performance indicators) of financial data of the publicly listed companies within the innovators landscape dataset. A key acquisition targets analysis, based on the insights generated during the course of this study, highlighting some of the promising early-to-mid stage business ventures that are likely to be acquired / merged. A case study on the assessment of business risks, based on some of the major risk categories that are usually discussed in the industry, namely operations-related risks, business-related risks, financial / asset-related risks, product / technology risks, and others (social, economic, environmental and political risks). A case study where investors have exited various women’s digital health-related ventures, offering insights on return on investments received (based on availability of data). Leveraging the abovementioned details, the report offers an informed opinion on the future outlook for investors in the women’s digital health market.   The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:   Type of Solution Applications / Software Devices Services   Therapeutic Application Area Fetal Health General Wellness Menstrual Cycle Pelvic Care Reproductive Health / Fertility   Key Geographical Regions North America Europe Asia-Pacific Latin America Middle East and North Africa                                                                                          Key Questions Answered What are the key application areas of the FemTech industry? Who are the innovators offering women’s digital health solutions? What type of women’s digital health products / solutions are being offered by the innovator companies? What are the key value propositions offered by players engaged in the women’s digital health domain? What is the relative competitiveness of different players offering products / solutions focused on women’s health? Who are the key investors that are actively supporting the development and commercialization of women’s digital health products / solutions? What are the anticipated fundamental and technical trends of financial data of publicly listed companies within the innovator landscape? Who are the potential acquisition targets for investors in the women’s digital health sector? What are the major risks for investors seeking to tap into the women’s digital health domain? What is the estimated return on investments received by the investors? How is the current and future market opportunity related to women’s digital health likely to be distributed across key market segments?   Get more details on the report https://www.rootsanalysis.com/reports/opportunities-in-women-digital--health-market.html   You may also be interested in the following titles: Blockchain Technology in Healthcare Market  Autoinjectors   You may also like to learn what our experts are sharing in Roots educational series: Cell Therapy – The Revolutionary Therapeutic Modality: All Set To Obliterate Oncological Disorders 4D Bioprinting Market: Key Trends   About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.   Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com